Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pittel

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
Journal of Neural Transmission. Supplementum|November 29, 2002
Impact of muscarinic agonists for successful therapy of Alzheimer's diseaseA Fisher, R Brandeis, R Haring, et al.
Annals of the New York Academy of Sciences|September 24, 1993
Selective signaling via unique M1 muscarinic agonistsA Fisher, E Heldman, D Gurwitz, et al.
Drug Design and Discovery|January 1, 1993
Progress in medicinal chemistry of novel selective muscarinic agonistsA Fisher, Y Karton, E Heldman, et al.
Brain Research. Developmental Brain Research|July 31, 2003
Activity-dependent neuroprotective protein: a novel gene essential for brain formationAlbert Pinhasov, Shmuel Mandel, Arkady Torchinsky, et al.
Biochemical and Biophysical Research Communications|August 30, 1994
Amyloid precursor protein secretion via muscarinic receptors: reduced desensitization using the M1-selective agonist AF102BR Haring, D Gurwitz, J Barg, et al.
Biochemical and Biophysical Research Communications|August 4, 1995
NGF promotes amyloid precursor protein secretion via muscarinic receptor activationR Haring, D Gurwitz, J Barg, et al.
Journal of Physiology, Paris|October 28, 1998
Novel m1 muscarinic agonists in treatment and delaying the progression of Alzheimer's disease: an unifying hypothesisA Fisher, R Brandeis, R Haring, et al.
Journal of Molecular Neuroscience : MN|September 23, 2003
M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapyAbraham Fisher, Zipora Pittel, Rachel Haring, et al.
Annals of the New York Academy of Sciences|January 17, 1996
M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical updateA Fisher, E Heldman, D Gurwitz, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Journal of Neural Transmission. Supplementum|November 29, 2002
Impact of muscarinic agonists for successful therapy of Alzheimer's diseaseA Fisher, R Brandeis, R Haring, et al.
Annals of the New York Academy of Sciences|September 24, 1993
Selective signaling via unique M1 muscarinic agonistsA Fisher, E Heldman, D Gurwitz, et al.
Drug Design and Discovery|January 1, 1993
Progress in medicinal chemistry of novel selective muscarinic agonistsA Fisher, Y Karton, E Heldman, et al.
Brain Research. Developmental Brain Research|July 31, 2003
Activity-dependent neuroprotective protein: a novel gene essential for brain formationAlbert Pinhasov, Shmuel Mandel, Arkady Torchinsky, et al.
Biochemical and Biophysical Research Communications|August 30, 1994
Amyloid precursor protein secretion via muscarinic receptors: reduced desensitization using the M1-selective agonist AF102BR Haring, D Gurwitz, J Barg, et al.
Biochemical and Biophysical Research Communications|August 4, 1995
NGF promotes amyloid precursor protein secretion via muscarinic receptor activationR Haring, D Gurwitz, J Barg, et al.
Journal of Physiology, Paris|October 28, 1998
Novel m1 muscarinic agonists in treatment and delaying the progression of Alzheimer's disease: an unifying hypothesisA Fisher, R Brandeis, R Haring, et al.
Journal of Molecular Neuroscience : MN|September 23, 2003
M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapyAbraham Fisher, Zipora Pittel, Rachel Haring, et al.
Annals of the New York Academy of Sciences|January 17, 1996
M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical updateA Fisher, E Heldman, D Gurwitz, et al.
Pageof 7